
Opinion|Videos|May 12, 2025
A 50-Year-Old-Woman With cGVHD
Panelists discuss how patient education and multidisciplinary involvement are critical for early detection of chronic graft-vs-host disease (cGVHD).
Advertisement
Episodes in this series

Clinical Case Presentation (Part 1)
A 50-year-old woman underwent allogeneic transplant with reduced-intensity conditioning from a matched unrelated donor for mesenchymal stromal cells. Her donor was a cytomegalovirus-negative 45-year-old man, and GVHD prophylaxis was tacrolimus and mycophenolate mofetil.
At 7 months post transplant, she presented with:
- Lichen planus–like eruptions on back and upper chest
- Sclerotic features on lower trunk and thighs (22% body surface area)
- Oral and ocular dryness
- Mild joint stiffness in hands/wrists
- Mild dyspnea and fatigue
- Pulmonary function tests showing mild decline in DLCO with stable FEV1
The panel agreed this represents:
- Clear evidence of chronic GVHD with multiple organ involvement
- Moderate to severe cGVHD by National Institutes of Health (NIH) criteria
- Need for systemic immunosuppressive therapy
- Importance of thorough pulmonary evaluation, potentially including CT scan
All panelists use the NIH scoring system in their practices, with organ-specific assessments at each visit.
Advertisement
Related to this article

Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.

Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.

The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.

Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.

Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.

Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.

The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5
